Alteration in the drug disposition in the mouse model of diabetes/obesity.

对糖尿病小鼠模型药物代谢酶表达水平的研究表明，由于胰岛素水平的差异，肠道细胞色素P3A的表达差异是1型和2型糖尿病患者药物处置差异的机制之一。此外，基于生理学的药代动力学模型分析发现，抗糖尿病药物瑞格列奈水平的大幅增加与药物相互作用是通过抑制其肝脏吸收和代谢来解释的。

The investigation of the expression levels of drug metabolizing enzymes in diabetic mouse models suggested that the differential expression of intestinal CYP3A, due to the difference in insulin levels, is one of the mechanisms for the differences in drug disposition between type 1 and 2 diabetic patients. Furthermore, a drug interaction with a great increase in the level of repaglinide, an antidiabetic, was found to be explained by the inhibition of its hepatic uptake and metabolism based on a physiologically-based pharmacokinetic modeling analysis.